PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

Journal for ImmunoTherapy of Cancer

Volumn 1, Issue , 2013, Pages

  Escuin Ordinas, Helena ^a   Elliott, Mark W ^b   Atefi, Mohammad ^a   Lee, Michelle ^b   Ng, Charles ^a   Wei, Liu ^a   Comin Anduix, Begoña ^a,c   Montecino Rodriguez, Encarnacion ^c   Avramis, Earl ^c   Radu, Caius ^a   Sharp, Leslie L ^b,d   Ribas, Antoni ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

4 1BB; CD137; Colon cancer; Immune activating antibodies; PET imaging

Indexed keywords

3' HYDROXYMETHYL DDG; CD137 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; FLUORODEOXYGLUCOSE F 18; GLUCOSE DERIVATIVE; HERMES ANTIGEN; L SELECTIN; MAB9371 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CIRCULATING TUMOR CELL; COLON CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FLOW CYTOMETRY; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE; MACROPHAGE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; UPTAKE ASSAY;

EID: 84991032267     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-1-14     Document Type: Article

References (20)

1. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3(6):682-685.
2. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007, 7(2):95-106.
3. Vinay DS, Kwon BS: Role of 4-1BB in immune responses. Semin Immunol 1998, 10(6):481-489.
4. Vinay DS, Kwon BS: Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012, 11(5):1062-1070.
5. Wang C, Lin GH, McPherson AJ, Watts TH: Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009, 229(1):192-215.
6. Croft M: The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009, 9(4):271-285.
7. Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, Penuelas I, Dubrot J, Morales-Kastresana A, Perez-Gracia JL, Ochoa MC, et al: Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer research 2011, 71(3):801-811.
8. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013, 123(3):1371-1381.
9. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC, et al: Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012, 61(10):1721-1733.
10. Massoud TF, Gambhir SS: Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003, 17(5):545-580.
11. Phelps ME, Schelbert HR, Mazziotta JC: Positron computed tomography for studies of myocardial and cerebral function. Ann Intern Med 1983, 98(3):339-359.
12. Singh AS, Radu CG, Ribas A: PET imaging of the immune system: immune monitoring at the whole body level. Q J Nucl Med Mol Imaging 2010, 54(3):281-290.
13. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, et al: 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186(1):47-55.
14. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15(23):7412-7420.
15. Shu CJ, Guo S, Kim YJ, Shelly SM, Nijagal A, Ray P, Gambhir SS, Radu CG, Witte ON: Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci USA 2005, 102(48):17412-17417.
16. Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A: The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother 2010, 33(8):759-768.
17. Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH: Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 2003, 362(9388):945-950.
18. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J: Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 2010, 51(3):340-346.
19. Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, Blokx WA, et al: Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci USA 2011, 108(45):18396-18399.
20. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, Phelps ME, Witte ON: Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med 2008, 14(7):783-788.